NCT04641312View on ClinicalTrials.gov

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

December 21, 2021

Conditions
HealthyType 2 Diabetes
Interventions
DRUG

LY3457263

Administered SC

DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (2)

41460

Profil Institut für Stoffwechselforschung, Neuss

55116

Profil Mainz, Mainz

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04641312 - A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter